Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosemary Millen

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|January 17, 2017
Impact of celecoxib on inflammation during cancer surgery: a randomized clinical trialJonathan G Hiller, Shienny Sampurno, Rosemary Millen, et al.
Journal of Visualized Experiments : Jove|May 17, 2021
Medium-Throughput Drug- and Radiotherapy Screening Assay using Patient-Derived OrganoidsMarrit Putker, Rosemary Millen, René Overmeer, et al.
Human Vaccines & Immunotherapeutics|February 24, 2018
Levels of regulatory B cells do not predict serological responses to hepatitis B vaccineMaria Bolther, Karen Lise Dahl Andersen, Martin Tolstrup, et al.
Hemasphere|August 28, 2024
Long-term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximabArnon P Kater, Barbara F Eichhorst, Carolyn J Owen, et al.
Oncoimmunology|September 14, 2016
Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancerRosemary Millen, Jordane Malaterre, Ryan S Cross, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2024
Epidermal growth factor receptor (EGFR) is a target of the tumor-suppressor E3 ligase FBXW7Matteo Boretto, Maarten H Geurts, Shashank Gandhi, et al.
Clinical & Translational Immunology|September 21, 2020
CD8<sup>+</sup> tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous <i>de novo</i> metastatic colorectal carcinoma do not track with survivalRosemary Millen, Shona Hendry, Vignesh Narasimhan, et al.
Blood|February 26, 2025
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLLArnon P Kater, Rosemary Anne Harrup, Thomas J Kipps, et al.
Med (New York, N.Y.)|May 13, 2023
Patient-derived head and neck cancer organoids allow treatment stratification and serve as a tool for biomarker validation and identificationRosemary Millen, Willem W B De Kort, Mandy Koomen, et al.
Nature Immunology|November 27, 2023
Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cellsPatricia Hernández-López, Eline van Diest, Peter Brazda, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|January 17, 2017
Impact of celecoxib on inflammation during cancer surgery: a randomized clinical trialJonathan G Hiller, Shienny Sampurno, Rosemary Millen, et al.
Journal of Visualized Experiments : Jove|May 17, 2021
Medium-Throughput Drug- and Radiotherapy Screening Assay using Patient-Derived OrganoidsMarrit Putker, Rosemary Millen, René Overmeer, et al.
Human Vaccines & Immunotherapeutics|February 24, 2018
Levels of regulatory B cells do not predict serological responses to hepatitis B vaccineMaria Bolther, Karen Lise Dahl Andersen, Martin Tolstrup, et al.
Hemasphere|August 28, 2024
Long-term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximabArnon P Kater, Barbara F Eichhorst, Carolyn J Owen, et al.
Oncoimmunology|September 14, 2016
Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancerRosemary Millen, Jordane Malaterre, Ryan S Cross, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2024
Epidermal growth factor receptor (EGFR) is a target of the tumor-suppressor E3 ligase FBXW7Matteo Boretto, Maarten H Geurts, Shashank Gandhi, et al.
Clinical & Translational Immunology|September 21, 2020
CD8<sup>+</sup> tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous <i>de novo</i> metastatic colorectal carcinoma do not track with survivalRosemary Millen, Shona Hendry, Vignesh Narasimhan, et al.
Blood|February 26, 2025
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLLArnon P Kater, Rosemary Anne Harrup, Thomas J Kipps, et al.
Med (New York, N.Y.)|May 13, 2023
Patient-derived head and neck cancer organoids allow treatment stratification and serve as a tool for biomarker validation and identificationRosemary Millen, Willem W B De Kort, Mandy Koomen, et al.
Nature Immunology|November 27, 2023
Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cellsPatricia Hernández-López, Eline van Diest, Peter Brazda, et al.
Pageof 2